EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY

被引：2
|
作者：
Schmid, Peter [1 ]
Park, Yeon Hee [2 ]
Munoz-Couselo, Eva [3 ]
Kim, Sung-Bae [4 ]
Sohn, Joohyuk [5 ]
Im, Seock-Ah [6 ]
Holgado, Esther [7 ]
Foukakis, Theodoros [8 ,9 ]
Kuemmel, Sherko [10 ]
Dent, Rebecca [11 ]
Sun, Yuan [12 ]
Huang, Lingkang [12 ]
Yearley, Jennifer [12 ]
Jelinic, Petar [12 ]
Karantza, Vassiliki [12 ]
Cortes, Javier [3 ]
机构：
[1] Ctr Expt Canc Med, London, England
[2] Samsung Med Ctr, Seoul, South Korea
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea
[7] Ramon y Cajal Univ, Madrid, Spain
[8] Karolinska Inst, Solna, Sweden
[9] Karolinska Univ Hosp, Theme Canc, Breast Canc Ctr, Solna, Sweden
[10] Kliniken Essen Mitte, Essen, Germany
[11] Int Breast Canc Ctr Quironsalud Grp, Singapore, Singapore
[12] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.338
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
338
引用
收藏
页码：A364 / A364
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)
    Schmid, P.
    Park, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Yin, L.
    Ding, Y.
    Tryfonidis, K.
    Cortes, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Pembrolizumab (pembro) plus chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173
    Schmid, Peter
    Park, Yeon Hee
    Munoz-Couselo, Eva
    Kim, Sung-Bae
    Sohn, Joohyuk
    Im, Seock-Ah
    Holgado, Esther
    Wang, Yang
    Dang, Thao
    Aktan, Gursel
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Cortes, J.
    ark, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
    Schmid, P.
    Salgado, R.
    Park, Y. H.
    Munoz-Couselo, E.
    Kim, S. B.
    Sohn, J.
    Im, S. -A.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Yin, L.
    Wang, A.
    Tryfonidis, K.
    Karantza, V.
    Cortes, J.
    Loi, S.
    ANNALS OF ONCOLOGY, 2020, 31 (05) : 569 - 581
  • [6] Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
    Dent, Rebecca
    Cortes, Javier
    Park, Yeon Hee
    Munoz-Couselo, Eva
    Kim, Sung-Bae
    Sohn, Joohyuk
    Im, Seock-Ah
    Holgado, Esther
    Foukakis, Theodoros
    Kuemmel, Sherko
    Yearley, Jennifer
    Wang, Anran
    Nebozhyn, Michael
    Huang, Lingkang
    Cristescu, Razvan
    Jelinic, Petar
    Karantza, Vassiliki
    Schmid, Peter
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [7] Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
    Nanda, Rita
    Chow, Laura Q. M.
    Dees, E. Claire
    Berger, Raanan
    Gupta, Shilpa
    Geva, Ravit
    Pusztai, Lajos
    Pathiraja, Kumudu
    Aktan, Gursel
    Cheng, Jonathan D.
    Karantza, Vassiliki
    Buisseret, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) : 2460 - +
  • [8] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Diab, Sami
    CANCER RESEARCH, 2018, 78 (04)
  • [9] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Young, Louise
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 176 - 176
  • [10] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    CANCER RESEARCH, 2017, 77
12345